NIH-funded research R01 grant

Improving communication and medication adherence for Black patients with lupus

Official title: CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus

Funded at Duke University · NIH-10934355 · Data updated 2026-11-12

This study is all about helping Black patients with lupus feel more comfortable talking to their doctors so they can stick to their medications better, by training healthcare providers in better communication and understanding the specific challenges these patients face.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionDuke University
NIH-funded
Lab location1 site (Durham, United States)
Project startSeptember 23, 2023
Project endJune 30, 2028
Funding year2024
Award (this year)$669,780
NIH project number5R01MD018977-02
Project IDNIH-10934355 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are Black patients diagnosed with systemic lupus erythematosus who struggle with medication adherence.

Less likely to help

Patients who are not Black or those without a diagnosis of systemic lupus erythematosus may not benefit from this research.

What this research studies

This research focuses on enhancing communication between healthcare providers and Black patients suffering from systemic lupus erythematosus (SLE) to improve medication adherence. It aims to address the unique challenges faced by these patients, including mistrust in the medical system and poor communication quality during clinic visits. The intervention, called CO-LEADER, involves training clinicians in culturally appropriate communication techniques and utilizing pharmacy refill data alongside patient-reported barriers to adherence. By fostering better communication and understanding, the study seeks to reduce racial disparities in health outcomes for SLE patients.

Why it matters

Potential benefit: If successful, this research could lead to improved medication adherence and better health outcomes for Black patients with lupus.

How similar studies have gone: Previous research has shown that improving patient-provider communication can enhance medication adherence, suggesting that this approach may be effective.

Where this research is happening

  • Duke University
    Durham, United States
    Active

Researchers

  • Principal investigator: Sun, Kai — Duke University
  • Study coordinator: Sun, Kai

Related research

Other NIH-funded projects on the same topics.

  • Better communication and medication support for people with lupus

    This project trains clinicians and uses pharmacy refill records plus patient-reported barriers to help Black people with lupus take their medicines more reliably.

    NIH research Duke University · Durham, United States · NIH-11310777

  • Immunostimulatory short non-coding RNAs and lupus

    A study in people with lupus looks at tiny RNA pieces that may spark inflammation, to understand if they drive disease activity.

    NIH research Thomas Jefferson University · Philadelphia, United States · NIH-11497703

  • Antiviral factors that limit HIV in people with SLE

    Researchers at Howard University are studying how immune factors in people with lupus may help limit HIV infection.

    NIH research Howard University · Washington, United States · NIH-11470887

  • Mechanistic clues about lupus from immune disorders

    This grant looks at why certain immune disorders in people with genetic immune problems lead to lupus-like symptoms, by studying patients and mouse models.

    NIH research Seattle Children's Hospital · Seattle, United States · NIH-11449228

  • Subjective thinking challenges in adults with lupus as they age

    This grant aims to understand how lupus-related cognitive problems affect adults, especially older adults, and tests a real-time method to track daily fluctuations in those symptoms.

    NIH research Hospital for Special Surgery · New York, UNITED STATES · NIH-11442899

  • Mitochondrial targets of antibodies in lupus (SLE)

    A Johns Hopkins-led study will identify which mitochondrial membrane proteins are targeted by autoantibodies in lupus patients to understand how these immune attacks fuel the disease.

    NIH research Johns Hopkins University · Baltimore, United States · NIH-11440181

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.